Drug-device Combinations: The Global Market

Report Code: PHM045B

Publish Date: Jan 2010

Publisher: BCC Publishing

Category: Pharmaceuticals

Customize This Report

Single User License: $2500

Member Price: FREE

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

  • Overall sales of drug device combination products were $12 billion in 2008 and $13.7 billion in 2009. This is projected to reach  $27 billion in 2014 at a compound annual growth rate (CAGR) of 14.5%
  • Sales in coronary stents Products were nearly $4.4 billion in 2008 and $4.8 billion in 2009. This market is projected to reach $7.4 billion in 2014, for a 5-year CAGR of 9%.
  • Photodynamic therapies market was $1.3 billion in 2008, which increased slightly in 2009 to $1.5 billion. This market is projected to reach approx $2.6 billion in 2014, for a 5-year CAGR of 11.6%.

INTRODUCTION 

STUDY GOALS AND OBJECTIVES
 
This report discusses key markets for drug device combination products. It provides descriptions of technologies and products, a review of the status of R&D initiatives and a forecast of the market through 2014. Company profiles and a patent analysis are provided as well. Example product categories that are covered include drug-eluting stents (DES), drug-eluting beads (DEB), antimicrobial catheters, antibiotic-loaded bone cements, glass ionomer cements, bone graft substitutes, antibacterial releasing dental restorative materials, biologic wound care products such as collagen-based dressings as therapeutic agents for wound healing, drug device combination products for ocular applications, photodynamic therapy, and other important niches. 
  
REASONS FOR DOING THIS STUDY AND ITS IMPORTANCE
 
Products that combine a drug or biologic with a device, such as drug-eluting stents and drug-delivery systems, can offer valuable approaches for treating diseases. In addition, developments in cell-based therapeutics, progenitor cell exploitation, growth factor delivery and advanced formulation strategies are becoming the basis of even more advanced combination device strategies. Technology advancements in the drug device combination market have been of considerable import in recent years and the pace of activity seems to be quickening with the appearance of many development-stage companies.
 
Especially since the approval of Johnson & Johnson’s Cypher drug-eluting stent in 2003 and Boston Scientific’s Taxus drug-eluting stent in 2004, drug-device combination products have attracted significant medical and media attention. But, combination products are subject to intense regulatory scrutiny for the issues of safety and effectiveness. Teams of device and drug product reviewers at a number of FDA centers are dedicated to evaluating such products. Thus, the bar is very high for FDA product approvals and consequently some combination products in certain categories are very small in number. For example, the entire fibrin sealant market is shared by only five FDA-approved products. Beyond drug-eluting stents and other categories noted above, combination products subject to FDA scrutiny include innovative drug-delivery systems, hemostatic sealants, photodynamic-therapy systems, gene-therapy systems, and products for many other investigational treatments.
 
The development of the market for combination products is closely related to another dynamic and fast growing healthcare segment generally termed “drug-delivery systems”. “Delivery systems” represents a vast area of research and development within biomaterials and medicine and the demand for sophisticated drug-delivery devices is behind many novel product developments. Advanced drug-delivery devices offer increased efficiency, improved performance and convenience.
 
INTENDED AUDIENCE
 
With its broad scope and in-depth analyses, this study will prove to be a valuable resource, particularly for anyone involved with or interested in the future of the fast growing drug device combination market. This study will be particularly useful for researchers, laboratory and government personnel working in research or company settings, as well as business professionals involved with drug and device development. It also will be of value to potential investors and members of the general public interested in acquiring a business-oriented view of a key health care sector in the economy. The projections, forecasts, and trend analyses found in this report provide readers with the necessary data and information for decision-making.
 
SCOPE AND FORMAT OF REPORT
 
In preparing this report, an overall study of the drug device combination market was undertaken. Related areas, such as drug delivery systems and nanotechnology, were key to the analysis as well, as newer areas such as nanotechnology, foreshadow likely product developments in the years ahead. All major aspects of the drug device combination market are addressed including identification of current and future technologies, products, market segments/end markets, and government and regulatory agencies. Participating companies are discussed in light of technological strengths and weakness, relative market share, marketing strengths, and innovative marketing practices. Included is a detailed discussion of the current regulatory environment for drug-device combination products and how this is affecting development and approval of such products.
 
METHODOLOGY AND INFORMATION SOURCES
 
Data for this study were collected using both primary and secondary data research techniques. A literature search was conducted covering scientific, medical, business and technical documents, as well as patents. Since most segments of the drug device combination market are not routinely measured, BCC derived estimates from a variety of sources. Whenever market estimates are derived, they are fully noted. All forecasts are in current (nominal) dollars, unadjusted for inflation. 
 
ANALYST CREDENTIALS
 
Research analyst Kevin Gainer holds both B.A. and M.A. degrees in quantitative economic analysis and has 25 years of economic, industry intelligence and market research experience. He is the author of six published books and dozens of technical papers, analyses, and studies published in conference proceedings, including many unpublished within corporations. He has worked as a Research Editor and Project Analyst at BCC Research since 1985, and has authored numerous BCC technology market research reports.
 
BCC ONLINE SERVICES
 
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
 
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers
DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW
Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Drug-device Combinations: The Global Market244Free
Chapter- 1: INTRODUCTION4Free
Chapter- 2: EXECUTIVE SUMMARY4Free
Chapter- 3: CURRENT STATUS OF THE DRUG DEVICE COMBINATION INDUSTRY9Free
Chapter- 4: REGULATORY PROCESS AND ISSUES7Free
Chapter- 5: NANOTECH COMBINATION PRODUCTS17Free
Chapter- 6: DRUG-ELUTING CORONARY STENTS15Free
Chapter- 7: PHOTODYNAMIC THERAPY12Free
Chapter- 8: ANTIMICROBIALS AND OTHER MEDICAL DEVICE COATINGS8Free
Chapter- 9: ANTIMICROBIAL CATHETERS8Free
Chapter- 10: DRUG-ELUTING BEADS14Free
Chapter- 11: BONE CEMENTS INCLUDING ANTIBIOTIC9Free
Chapter- 12: BONE GRAFT SUBSTITUTES39Free
Chapter- 13: WOUND CARE PRODUCTS INCLUDING BIOLOGICAL DRESSINGS 14Free
Chapter- 14: DRUG DEVICE COMBINATION PRODUCTS FOR OCCULAR APPLICATIONS7Free
Chapter- 15: IMPLANTABLES AS DRUG DEVICE COMBINATIONS4Free
Chapter- 16: RELATED DRUG DEVICE COMBINATIONS OF RELEVANCE10Free
Chapter- 17: PATENT ANALYSIS17Free
Chapter- 18: INDUSTRY STRUCTURE AND COMPANY PROFILES42Free
Chapter- 19: APPENDIX4Free
Published - Jun-2005| Analyst - Lynn Gray| Code - PHM045A

Report Highlights

  • The total market for drug-device combinations worldwide was valued at $5.4 billion in 2004 and is expected to rise at an average annual growth rate (AAGR) of 13.6% to $11.5 billion in 2010.
  • The star category is drug-eluting stents that will continue to show average annual growth of 11.5%. This will result in the market doubling to $8 billion in 2010.
  • With the exception of bone graft substitutes and antibiotic bone cements, all categories will show double-digit growth.
  • The U.S. dominates the market for drug-device combination products, mainly because the largest-selling drug-eluting stents have been enthusiastically accepted in this market and consequently are penetrating the market more quickly than in Europe.

Related Reports

Recent Reports

Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - PHM204C

The global market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $2.8 billion in 2024 to reach $5.0 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.

Rare Disease Diagnostics: Technologies and Global Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - PHM227B

The global market for rare disease diagnostics is estimated to increase from $21.6 billion in 2024 to reach $34.7 billion by 2029, at a compound annual growth rate (CAGR) of 9.9% from 2024 through 2029.

Breakthrough Therapies: Market Dynamics and Investment Opportunities

Published - Dec 2024 | Publisher - BCC Publishing | Code - PHM176B

The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.

Softgel Capsules: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM244B

The global market for softgel capsules was valued at $7.4 billion in 2023. The market is expected to grow from $7.9 billion in 2024 to $11.5 billion by 2029, at a compound annual growth rate, or CAGR, of 7.7% from 2024 through 2029.

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Top Trending Reports

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Medical Devices Industry: Competitive Landscape

Published - Nov 2024 | Publisher - BCC Publishing | Code - MDS010C

The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC239C

The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Drug-device Combinations: The Global Market
Customize Report